Gilead Sciences (GILD) Downgraded by BidaskClub

BidaskClub cut shares of Gilead Sciences (NASDAQ:GILD) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.

GILD has been the topic of several other reports. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the company a hold rating in a research note on Wednesday, January 3rd. Oppenheimer assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They issued a market perform rating on the stock. Mizuho increased their price target on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a buy rating in a research note on Wednesday, November 8th. Leerink Swann increased their price target on shares of Gilead Sciences from $87.00 to $89.00 and gave the company a market perform rating in a research note on Thursday, October 5th. Finally, BMO Capital Markets dropped their price target on shares of Gilead Sciences from $89.00 to $83.00 and set an outperform rating on the stock in a research note on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of Buy and an average price target of $85.03.

Shares of Gilead Sciences (NASDAQ GILD) traded down $0.04 during trading on Tuesday, reaching $79.02. 6,342,448 shares of the company’s stock traded hands, compared to its average volume of 8,150,000. The stock has a market capitalization of $103,190.00, a price-to-earnings ratio of 8.99, a P/E/G ratio of -1.68 and a beta of 1.13. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.75 earnings per share. sell-side analysts predict that Gilead Sciences will post 8.53 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.63%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.66%.

In other news, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders sold 461,666 shares of company stock valued at $34,072,567 over the last three months. Corporate insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC lifted its holdings in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Northern Trust Corp lifted its holdings in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. Toronto Dominion Bank lifted its holdings in shares of Gilead Sciences by 19.0% during the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after purchasing an additional 75,364 shares during the period. Finally, Fagan Associates Inc. lifted its holdings in shares of Gilead Sciences by 2.6% during the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after purchasing an additional 845 shares during the period. 75.94% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/01/13/gilead-sciences-gild-downgraded-by-bidaskclub.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply